

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Pharmacia Corporation) DOCKET NO.: 6193/1
SERIAL NO.: 10/072,492) GROUP ART UNIT: 1615
FILED: February 5, 2002) EXAMINER: Rachel Bennett
TITLE: COMPOSITION AND METHOD FOR RECTAL DELIVERY OF A
LINCOSAMIDE ANTIBACTERIAL DRUG

1615 \$
RECEIVED
JUL 25 2003
TECH CENTER
7/25/03

CERTIFICATE OF MAILING

I, Susan Gawlik, hereby certify that this communication and recited enclosures are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, U.S. Patent and Trademark Office, Alexandria, VA 22313-1450 on: July 14, 2003.

Signed: Susan B. Gawlik

Commissioner for Patents
P.O. Box 1450
U.S. Patent and Trademark Office
Alexandria, VA 22313-1450

Dear Sir:

PETITION FOR EXTENSION OF TIME

Applicants hereby petition for an extension of time of one month to respond to an Office Action mailed March 14, 2003, in prosecution of the above-referenced patent application. A shortened statutory time period for response of three months was set by the Office Action. In connection with this petition, please charge \$110.00 or the sum required under 37 C.F.R. §1.17(a)(1) to Deposit Account No. 19-1025.


AMENDMENT AND RESPONSE, UNDER 37 C.F.R. §1.111

I. INTRODUCTION

Applicants respectfully submit the following amendment and remarks in response to an Office Action, mailed March 14, 2003. The amendment is presented in the revised format now permitted. Waiver of the provisions of 37 C.F.R. §1.121 (a)-(d) is respectfully requested.

II. AMENDMENT

Please amend claims 11, 25, 27, and 35, as follows:

- 
1. (original) A suppository composition for rectal administration of a lincosamide antibacterial drug, comprising an antimicrobially effective amount of the lincosamide dispersed in a Hard Fat suppository base, wherein the lincosamide is in the form of solid particles.
 2. (original) The composition of claim 1, wherein the lincosamide is present in a form selected from the group consisting of a lincosamide salt and a lincosamide ester.
 3. (original) The composition of claim 1, wherein the lincosamide is present in the form of a lincosamide phosphate.
 4. (original) The composition of claim 1 wherein the lincosamide is present in said composition in an amount from about 0.1 % by weight of the entire composition to about 60% by weight of the entire composition.
 5. (original) The composition of claim 1 wherein the lincosamide is selected from the group consisting of pirlimycin and lincomycin.
 6. (original) The composition of claim 1 wherein the lincosamide is clindamycin.
 7. (previously amended) The composition of claim 6 wherein the clindamycin is present in said composition in an amount from about 1.5 % by weight of the entire composition to about 7.5% by weight of the entire composition.
 8. (original) The composition of claim 1 wherein said Hard Fat has a β polymorphic form which has a flow point in the range from 30 °C to 40 °C.
 9. (original) The composition of claim 1 wherein said Hard Fat has a β polymorphic form which has a flow point of 37 °C or less.